IMU-856 is under clinical development by Immunic and currently in Phase I for Celiac Disease. According to GlobalData, Phase I drugs for Celiac Disease does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the IMU-856 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMU-856 overview
IMU-856 is under development for the treatment of Crohn's disease, irritable bowel syndrome, ulcerative colitis and celiac disease. It is administered through oral route. The drug candidate acts by targeting Sirtuin 6 (SIRT6).
See Also:
Immunic overview
Immunic (Immunic Therapeutics), formerly Vital Therapies, is a biopharmaceutical company that discover, develops and commercializes oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company’s pipeline products include IMU-838, a selective immune modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD) and other chronic inflammatory and autoimmune diseases; IMU-856, an orally small molecule modulator to treat intestinal barrier function; and IMU-935, an immunology therapy targeting ROR?t and Th17. It is also evaluating therapies targeting primary sclerosing cholangitis (PSC), and guillain-barre syndrome (GBS). Immunic Therapeutics works in collaboration with pharmaceutical and biopharmaceutical companies to develop its products. Immunic Therapeutics is headquartered in New York City, New York, the US.
For a complete picture of IMU-856’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
